Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148720 · ClinicalTrials.gov registry record · Phase 2
Capecitabine in Women With Operable Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00148720 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 80 participants.
The verdict
NCT00148720, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) taking capecitabine for 12 weeks before surgery will have on women with breast cancer.
Interventions
- DRUG Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148720
The ClinicalTrials.gov registry entry for NCT00148720 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capecitabine is the first listed.
NCT00148720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00148720 about?
NCT00148720 is a clinical study titled "Capecitabine in Women With Operable Breast Cancer". The purpose of this study is to find out what effects (good and bad) taking capecitabine for 12 weeks before surgery will have on women with breast cancer.
What is the current status of trial NCT00148720?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-09.
What interventions are being tested in trial NCT00148720?
The interventions under investigation include: Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00148720?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.